News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aesica Appoints Ian Muir To Newly Created Commercial Managing Director Position



2/3/2014 9:15:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

3rd February 2014 - Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced the appointment of Ian Muir to the newly created position of Commercial Managing Director, effective from 24th February. The position is reflective of the company’s plans for further global expansion and has international responsibility for all aspects of the commercial business.

The creation of the role reflects the strategic decision of Aesica to focus on its core commercial activities, with a global leadership structure primarily dedicated to the customer base. Ian Muir’s responsibilities cross all three of the company’s service offerings in API manufacture, formulation development and formulated products and he will lead the expansion of the business into new growth markets such as China and Japan.

Reporting directly to the CEO, Dr. Robert Hardy, Ian will be joining the Aesica Board. Under the new structure, Business Development, Sales and Marketing, Key Account and Product Management across Aesica will report directly to Ian who will be based at the company’s headquarters, in Newcastle, UK.

Ian holds a PhD in Pharmaceutical Science and with over 20 years’ experience in the pharmaceutical industry, his most recent role was at Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms. He has significant commercial experience in contract manufacturing roles for large pharmaceutical companies located in Europe, the US and Australia and has been responsible for leading both R&D activities and commercial manufacturing operations. Furthermore, in previous roles, he grew a drug delivery business including in licensing key technologies from third parties in Japan and the rest of the world in controlled release tablet technology.

Dr. Robert Hardy, CEO said: “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”

Commenting on his new position, Ian said: “Aesica is fast growing, global CDMO with strong prospects for continued expansion supported by a solid client base and a full-service offering. I look forward to working with the company’s skilled personnel across all its sites to aid the company in achieving its vision to become the number 1 supplier of APIs and formulated products to the pharmaceutical industry.”

About Aesica:

Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.

The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

- Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover.

- The company currently employs approximately 1,300 people.

- In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.

- The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.

- Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011.

For media enquiries, please contact Tristan Jervis or Alex Heeley on: +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Aesica
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES